NAD tells Metabolic Research to drop claims
This article was originally published in The Tan Sheet
Executive Summary
Metabolic Research disagrees with the National Advertising Division's recommendations to discontinue claims that people who take Stemulite experience "deep REM sleep, Increased Muscle Gain and Endurance, Increased Wellness and Energy." The firm said data in the New England Journal of Medicine and "similar resources" supports the claims. It added it "retained counsel to further review" claim documentation and has "every intention" of complying. NAD said a 17-person, 30-day study Metabolic Research submitted did not support the claims because it was too small, subjective and not placebo-controlled. The two got off to a rocky start when NAD attempted to contact the firm via a former employee at an incorrect address. The resulting delay did not give the firm enough time to response to NAD's request, the firm said. This prompted NAD to refer the case to the Federal Trade Commission (1"The Tan Sheet" Sept. 7, 2009). NAD reopened the case after the advertiser said it would participate
You may also be interested in...
Stemulite Marketer Learns NAD Expects Prompt Replies
Stemulite fitness dietary supplements marketer Metabolic Research Inc. finds that failing to reply promptly to a National Advertising Division inquiry can get a firm tossed from the self-regulatory frying pan into the FTC fire
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.